CD8A and melanoma: Baseline circulating CD8+ Tem frequencies correlate with better OS and clinical response in patients with advanced melanoma receiving anti-CTLA-4 [68,77,78], as well as in other cancer patients treated with PD1/PD-L1 axis inhibitor [33].